High vWF levels in patients with atrial fibrillation were associated with increased risks of all-cause death (RR 1.56; 95% CI 1.16 to 2.11, p=0.00400), cardiovascular death, MACE, stroke, and bleeding.
Meta-Analysis (n=7,449)
Are high von Willebrand factor (vWF) levels associated with increased risk of adverse clinical outcomes in patients with atrial fibrillation?
Elevated von Willebrand factor levels are a significant risk factor for poor prognosis, including death, stroke, and bleeding, in patients with atrial fibrillation.
Effect estimate: RR 1.56 (95% CI 1.16 to 2.11)
p-value: p=0.00400
BACKGROUND: It is unknown whether an abnormal level of von Willebrand factor (vWF) is correlated with the prognosis of patients with atrial fibrillation (AF) and current findings are controversial. This meta-analysis aimed to evaluate the association between vWF levels and the clinical prognosis of patients with AF. METHODS: We searched prospective cohort studies on PubMed, Embase, Web of Science, Cochrane Library and WanFang databases for vWF and adverse events of AF from inception of the databases to July 2019. The risk ratios of all-cause death, cardiovascular death, major adverse cardiac events (MACE), stroke and bleeding prognosis in patients with AF were analysed using a fixed-effects model or random-effects model, and all included studies were evaluated with heterogeneity and publication bias analysis. RESULTS: Twelve studies which included 7449 patients with AF were used in the meta-analysis. The average age was 71.3 years and the average follow-up time was 3.38 years. The analysis found that high vWF levels were associated with increased risks of all-cause death (RR 1.56; 95% CI 1.16 to 2.11, p=0.00400), cardiovascular death (RR 1.91; 95% CI 1.20 to 3.03, p=0.00600), MACE (RR 1.83; 95% CI 1.28 to 2.62, p=0.00090), stroke (RR 1.69; 95% CI 1.08 to 2.64, p=0.02000) and bleeding (RR 2.01; 95% CI 1.65 to 2.45, p<0.00001) in patients with AF. CONCLUSIONS: vWF is a risk factor for poor prognosis of AF, and patients with higher vWF levels have a higher risk of all-cause death, cardiovascular death, MACE, stroke and bleeding.
Ye et al. (Tue,) conducted a meta-analysis in Atrial fibrillation (n=7,449). High vWF levels vs. Lower vWF levels was evaluated on All-cause death (RR 1.56, 95% CI 1.16 to 2.11, p=0.00400). High vWF levels in patients with atrial fibrillation were associated with increased risks of all-cause death (RR 1.56; 95% CI 1.16 to 2.11, p=0.00400), cardiovascular death, MACE, stroke, and bleeding.